Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6628999 | 0.88 | CNR2 (0.49) | SMN1; SMN2PPARGPPARAKEAP1 | |
| SCHEMBL4063592 | 0.88 | CNR2 (0.49) | SMN1; SMN2PPARGPPARAKEAP1 | |
| SCHEMBL13498523 | 0.85 | HDAC3 (0.48) | GRIK1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3487610 | 0.82 | CES1 (0.53) | GRIK1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3544881 | 0.82 | GRIK1 (0.59) | GRIK1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3488478 | 0.81 | KMT2A (0.46) | GRIK1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1856639 | 0.80 | GRIK1 (0.72) | GRIK1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28314735 | 0.80 | GRIK1 (0.57) | GRIK1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28314730 | 0.80 | GRIK1 (0.57) | GRIK1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28315720 | 0.80 | GRIK1 (0.57) | GRIK1HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1512983-A | Compounds and compositions as cathepsins inhibitors | AXYSҩ�﹫˾ | 2004-07-14 | — | — | CN | claimed |
| CN-102417480-B | As the Spirocyclic nitriles of proteinase inhibitor | Sanofi-Aventis S. P. A. (FR) | 2015-08-26 | — | — | CN | disclosed |
| CN-102264695-B | Haloalkyl containing compounds as cysteine protease inhibitors | VIROBAY INC | 2014-11-05 | — | — | CN | disclosed |
| CN-101460462-B | Spirocyclic nitriles as protease inhibitors | SANOFI AVENTIS SPA | 2013-07-31 | — | — | CN | disclosed |
| CN-102417480-A | Spirocyclic nitriles as protease inhibitors | SANOFI AVENTIS | 2012-04-18 | — | — | CN | disclosed |
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | DAVID SAMUEL | 2010-02-25 | — | — | US | disclosed |
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | DAVID SAMUEL | 2010-02-25 | — | — | US | disclosed |
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | DAVID SAMUEL | 2010-02-25 | — | — | US | disclosed |
| EP-2139836-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | The Royal Institution for the Advancement of Learning/McGill University (CA) | 2010-01-06 | — | — | EP | disclosed |
| CN-101460462-A | Spirocyclic nitriles as protease inhibitors | SANOFI AVENTIS (FR) | 2009-06-17 | — | — | CN | disclosed |
| WO-2008122119-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008122119-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2008-10-16 | — | — | WO | disclosed |
| CN-1512983-A | Compounds and compositions as cathepsins inhibitors | AXYSҩ�﹫˾ | 2004-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048727-A1 | PERFLUOROKETONE COMPOUNDS AND USES THEREOF | PLA2G1B, PLA2G4B, PLA2G2E | GRIK1 260/4885HDAC3 3244/4885HDAC1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.